Posts by Tom

13C5-NAD+ Ammonium Salt

NAD+ is a coenzyme found in many living cells that participates in numerous metabolic reactions and has several essential roles in metabolism. For the monitoring of NAD+ levels and its concentrations in vivo, 13C5-NAD+ has been employed for screening of NAD+ samples in preclinical discovery studies. 1   Cas# NA (unlabelled 53-84-9)  13C5-NAD+  Purity > 96 %  Chemical Formula: C1613C5H30N8O14P2  Molecular Weight: 685.46 (free base : 668.42)           13C5-NAD+ is currently available from stock For price information please sent a request HERE Synonyms: Adenosine 5′-(trihydrogen diphosphate) 13C5 , P’→5′-ester with 3-(aminocarbonyl)-1-β-Dribofuranosylpyridinium hydroxide 13C5, inner salt; Pyridinium,
Read More

Northern-Dutch Life Science SMEs at Bio Europe Spring 2015

Facilitated by the Healthy Ageing Campus, eight northern–Dutch Life Science companies travelled to the International Bio–Europe Spring conference in Paris, namely: Integrex Research, Innocore Pharmaceuticals , Syncom, ABL, Angita, QPS, Sulfateq and Brains On-line. Bio-Europe Spring took place on 9 – 11 March and is one of the largest partnering conferences in Europe in the field of life sciences, with more than 2,000 participants from all over the world.   For the Dutch article about the conference, click HERE.                
Read More

Syncom at Drug Discovery Chemistry 2015

Syncom will be present at Drug Discovery Chemistry, April 21–23, 2015 at booth #27, Hilton San Diego Resort & SPA, San Diego, CA, USA. Also a poster will be presented, entitled: DESIGN, SYNTHESIS AND SAR OF SOLUBLE 4-FLUOROPHENYL-IMIDAZOLE P38-ALPHA MAPK, CK1-DELTA AND JAK2 KINASE INHIBITORS. Introduction of the poster: The p38α MAPK and JAK signaling pathways are elevated or dysregulated in many inflammatory and autoimmune diseases such as rheumatoid arthritis, osteoarthritis, asthma, chronic obstructive pulmonary disease, inflammatory bowel disease, Crohn’s disease, acute coronary syndrome, multiple sclerosis, diabetes mellitus and cancer. The CK1δ signaling pathway is involved in circadian rhythm and
Read More

Syncom partner Angita and Motac enter into joint research collaboration

Angita Pharmaceuticals and Motac enter into a joint research collaboration to evaluate AG-0029, a putative treatment for both the motor and cognitive symptoms in Parkinson’s disease. AG-0029, a combined dopamine D2 receptor agonist and histamine H3 receptor antagonist, was discovered by Angita and has been shown to have cognitive enhancing potential and PD-related motor improvements in rodent models. Motac will invest in the project to extend the existing proof-of-concept studies including evaluation of Parkinson’s disease-related motor and cognitive disturbances in the most relevant and translational models. Jointly, Angita and Motac aim to ensure the continued development of AG-0029, raising funds
Read More

Meet Syncom at the CPHI Worldwide 2014

Syncom will be present at the CPhI Worldwide 2014 Paris, France – October 7-9, 2014. CPhI Worldwide 2014 is a meeting of the global pharmaceutical community, covering ingredients, APIs, excipients, finished dosage, contract services, packaging, machinery and more. With 2,200 exhibitors, 30,000 senior pharma professionals from 140+ countries the CPhI Worldwide 2014 is a great opportunity to initiate contact or touch base on existing projects. Syncom is looking forward to the opportunity to meet you at the CPhI Worldwide 2014  
Read More